Another item can now be crossed off The Waiting Game list. ACC 2019 Late Breaking Clinical Trials were announced today. BETonMACE is not on the list. Back when I originally proposed ACC 2019 LBCT as a BETonMACE possibility, the company guidance was still 250 events/end of dosing by end of 2018. With the trial still ongoing and ACC 2019 less than 2 months away, it is not surprising at all that BETonMACE wasn't on the list. I don't even know if Resverlogix applied (application deadline was December 7, 2018). Anyways, May/June are the next candidates for scientific conference presentation of BETonMACE (see 2019 potential events list), where full data presentation would occur. If those are missed, then ESC 2019 at end of August/beginning of September becomes the number 1 suspect for full data presentation. I expect top-line in advance of full data, with top-line coming 1 to 3 months in advance of the full data. All must my opinion. DYODD.